Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

VYNE Therapeutics (VYNE) Revenue (2016 - 2025)

VYNE Therapeutics' Revenue history spans 10 years, with the latest figure at $100000.0 for Q2 2025.

  • For Q2 2025, Revenue fell 50.0% year-over-year to $100000.0; the TTM value through Dec 2025 reached $383000.0, down 23.71%, while the annual FY2025 figure was $570000.0, 14.0% up from the prior year.
  • Revenue reached $100000.0 in Q2 2025 per VYNE's latest filing, down from $200000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $295000.0 in Q2 2021 to a low of $29000.0 in Q4 2022.
  • Average Revenue over 5 years is $144944.4, with a median of $123500.0 recorded in 2022.
  • Peak YoY movement for Revenue: plummeted 97.48% in 2021, then soared 162.07% in 2023.
  • A 5-year view of Revenue shows it stood at $273000.0 in 2021, then tumbled by 89.38% to $29000.0 in 2022, then skyrocketed by 162.07% to $76000.0 in 2023, then grew by 9.21% to $83000.0 in 2024, then rose by 20.48% to $100000.0 in 2025.
  • Per Business Quant, the three most recent readings for VYNE's Revenue are $100000.0 (Q2 2025), $200000.0 (Q1 2025), and $83000.0 (Q4 2024).